HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Adverse renal effects of the AGE inhibitor pyridoxamine in combination with ACEi in non-diabetic adriamycin-induced renal damage in rats.

AbstractBACKGROUND/AIMS:
Advanced glycation end products (AGEs) are involved in diabetic nephropathy. The AGE inhibitor pyridoxamine (PM) is renoprotective in experimental chronic allograft nephropathy supporting its potential in non-diabetic renal damage.
METHODS:
We studied the effects of PM in adriamycin nephropathy (AN; 1.5 mg/kg i.v.). Six weeks after disease induction, treatment started with vehicle (VEH), lisinopril (ACEi; 75 mg/l drinking water), PM (2 g/l) and PM + lisinopril (PM/ACEi) (n = 12 per group) for 18 weeks. Age-matched healthy rats (n = 6) served as controls (CON).
RESULTS:
ACEi reduced proteinuria, blood pressure, and renal damage. PM gradually increased blood pressure and not affected proteinuria. In PM/ACEi the antiproteinuric and blood pressure-lowering effects of ACEi were abrogated during long-term treatment. Remarkably, creatinine, focal glomerulosclerosis and interstitial fibrosis were considerably increased under PM/ACEi. Pronounced hypercholesterolemia, which occurred in both PM-treated groups, was accompanied by marked glomerular lipid deposition.
CONCLUSION:
PM was not renoprotective in AN. By contrast, renal damage was aggravated when PM was combined with ACEi. Despite the fact that there is no current evidence that these findings apply to the drug as used in human diabetic nephropathy, we emphasize the importance of close monitoring of blood pressure, lipids and possible direct toxic effects in future studies with PM in renal patients, especially when combining PM with ACEi.
AuthorsFemke Waanders, Harry van Goor, Gerjan Navis
JournalKidney & blood pressure research (Kidney Blood Press Res) Vol. 31 Issue 5 Pg. 350-9 ( 2008) ISSN: 1423-0143 [Electronic] Switzerland
PMID19018148 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2008 S. Karger AG, Basel.
Chemical References
  • Angiotensin-Converting Enzyme Inhibitors
  • Glycosylation End Products, Advanced
  • Lipids
  • Pyridoxamine
  • Doxorubicin
  • Lisinopril
Topics
  • Angiotensin-Converting Enzyme Inhibitors
  • Animals
  • Blood Pressure
  • Doxorubicin (adverse effects)
  • Drug Interactions
  • Drug Therapy, Combination
  • Glycosylation End Products, Advanced (antagonists & inhibitors)
  • Kidney Diseases (chemically induced)
  • Lipids (blood)
  • Lisinopril (pharmacology)
  • Proteinuria
  • Pyridoxamine (adverse effects)
  • Rats

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: